Enfusion (ENFN)
(Delayed Data from NYSE)
$8.21 USD
+0.14 (1.73%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $8.22 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
ENFN 8.21 +0.14(1.73%)
Will ENFN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ENFN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENFN
Implied Volatility Surging for Enfusion (ENFN) Stock Options
Enfusion (ENFN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
ENFN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Enfusion, Inc. (ENFN) Q2 Earnings and Revenues Miss Estimates
STNE or ENFN: Which Is the Better Value Stock Right Now?
Implied Volatility Surging for Enfusion (ENFN) Stock Options
Other News for ENFN
Enfusion: Growth Should Accelerate In Coming Quarters
Enfusion, Inc. (ENFN) Q2 2024 Earnings Call Transcript
Morgan Stanley Keeps Their Buy Rating on Enfusion (ENFN)
Enfusion Inc (ENFN) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
ENFN Stock Earnings: Enfusion Misses EPS, Misses Revenue for Q2 2024